Minerva Neurosciences Inc (NASDAQ:NERV)
| 0.835 Delayed Data As of 3:59pm ET |  -0.0079 / -0.94%Today’s Change | 0.79 Today|||52-Week Range 3.69 | +4.24% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $38.1M |
Company Description
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Waltham, MA.
Contact Information
Minerva Neurosciences, Inc. 1601 Trapelo Road Waltham Massachusetts 02451 |
Employees
Shareholders
| Mutual fund holders | 40.10% |
| Individual stakeholders | 28.21% |
| Other institutional | 18.58% |
Top Executives
| Rémy Henri Luthringer | Executive Chairman & Chief Executive Officer |
| Geoff Race | President |
| Joseph Reilly | Chief Operating Officer & Senior Vice President |
| Fred Ahlholm | Chief Financial Officer & Senior VP-Finance |
| Michael Davidson | Chief Medical Officer |
